Nosis Bio
- Biotech or pharma, therapeutic R&D
Nosis Bio develops cell-targeted RNA medicines for therapeutic areas with high unmet need including fibrosis, immunology, inflammation, cardio-metabolic conditions, and neurology.
Nosis is developing a wholly owned pipeline of siRNA conjugate therapeutics focused on previously inaccessible cell types across complex tissues—including lung, CNS, kidney, small intestine, heart, muscle, adipose, and diverse immune cell populations.
Nosis also partners with leading pharmaceutical and research organizations to design and develop cell-targeted RNA medicines with payloads including siRNA, ASO, protein-drug conjugates, and radiotherapeutics.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}